Cottonseed-based drug shows promise in treating severe brain cancer
BIRMNGHAM, Ala. – An experimental drug derived from cottonseed shows promise in treating the recurrence of glioblastoma multiforme, widely considered the most lethal brain cancer, said researchers at the University of Alabama at Birmingham (UAB).
The new results are from a Phase II clinical trial of AT-101, a pill manufactured from a potent compound in cottonseed that overcomes the abnormal growth patterns of tumor cells. This cottonseed-based agent must be properly dosed and monitored by physicians.
In clinical tests, AT-101 halted the cancer’s progression in many of the 56 patients, said John Fiveash, M.D., an associate professor in the UAB Department of Radiation Oncology and the lead researcher on the new study.